Immunohistochemistry: The Scientist s Paintbrush. Amanda Vang, Landssjúkrahúsiđ

Transcription

1 Immunohistochemistry: The Scientist s Paintbrush Amanda Vang, Landssjúkrahúsiđ

2 Let s Talk about. Purpose: A new drug for Inflammatory Bowel Disease Project goal: Will the drug work in the intestines? Methods: Immunohistochemistry A tool to see the drug binding sites using color Results: Where we found the drug binding site in the intestines Current Experiments: Looking at Disease Groups

3 Participation Inflammatory Bowel Disease Cohort Total [n = 1682] Center China, Wuhan Croatia, Zagreb Cyprus, Nicosia Czech Republic, Praha [incl. Pediatric] Czech Republic, South Bohemian Region Denmark, Aarhus Kommune Denmark, Amager Denmark, Funen [incl. Pediatric] Denmark, Herlev [incl. Pediatric] Denmark, Herning Denmark, Viborg Incidence Estonia, Southern Estonia [incl. Pediatric] 9, Faroe Islands, Faroe Islands 73, Finland, Pirkanmaa 22, Greece, Ioannina 8, Greenland, Nuuk 16, Hungary, Veszprem province 20, Iceland, Iceland 24, Ireland, Adelaide and Meath 12, Israel, Beer Sheva and Northern Negev 9, Italy, Northern Italy 9, Lithuania, Kaunas city and district 7, Moldova, [Pediatric Center] 2, Moldova, Chisinau 3, Portugal, Vale de Sousa 10, Romania, Timis 3, Russia, Moscow 4, Spain, Vigo [incl. Pediatric] 18, Sweden, Linkoping 32, Sweden, Orebro 26, United Kingdom, Brent and Harrow 15, United Kingdom, Hull and East Yorkshire 17, ,78 5,27 10,80 9,80 8,91 18,42 19,99 28,85 20,38 17,08 29,46 Incident patients Background population Cohort East [n = 389] Background Reference: Center Incidence Incident patients population China, Wuhan 1, Nielsen KR, Jacobsen S, Olsen K, Jess T, Gaini S. Incidence and clinical Croatia, Zagreb 5, Czech characteristics Republic, Praha [incl. Pediatric] of inflammatory bowel disease 9,80 in the Faroe 25Islands during Czech Republic, South Bohemian Region 8, Estonia, Southern Estonia [incl. Pediatric] 9, Hungary, Róin Veszprem F, Róin provincej. Inflammatory bowel disease 20,33 of the Faroe Islands, Lithuania, Kaunas A city prospective and district epidemiologic study: 7,34 primary report. Scand J Moldova, [Pediatric Center] 2, Gastroenterol Suppl. 1989;170:44 46; discussion Moldova, Chisinau 3,66 10 Romania, Timis 3,61 24 Russia, Moscow 4,

4 Let s Talk about. Purpose: A new drug for Inflammatory Bowel Disease Project goal: Will the drug work in the intestines? Methods: Immunohistochemistry A tool to see the drug binding sites using color Results: Where we found the drug binding site in the intestines Current Experiments: Looking at Disease Groups

5 The Drug works in blood vessels By trapping toxic cells in the bloodstream

6 Where will the drug bind in human intestines? DRUG Can we locate the drug binding target? Webmd.com

7 Let s Talk about. Purpose: A new drug for Inflammatory Bowel Disease Project goal: Will the drug work in the intestines? Methods: Immunohistochemistry A tool to see the drug binding sites using color Results: Where we found the drug binding site in the intestines Current Experiments: Looking at Disease Groups

8 Preparing the intestine biopsies for immunohistochemistry Biopsy Biopsy in Wax Cut thin sections Mount sections on slides

9 Imunohistochemistry: A tool to see the drug binding sites using color

10 Let s Talk about. A new drug for Inflammatory Bowel Disease Will the drug work in the intestines? Immunohistochemistry: A tool to see inside cells using color What answers have we found using immunohistochemistry? What are we working on now?

11 Result: The drug binding site is located in the blood vessels of the intestine Blood Vessel Brown color =Drug binding site

12 Let s Talk about. A new drug for Inflammatory Bowel Disease Will the drug work in the intestines? Immunohistochemistry: A tool to see inside cells using color What answers have we found using immunohistochemistry? What are we working on now?

13 Current Experiment: Are there more drug binding sites in Ulcerative Colitis or Crohn s Disease? Specific drug for types of IBD types

14 Visualizing Phosphodiesterase 8A: a novel therapeutic target for autoimmune and inflammatory diseases Maciej Kaminski, Kári R. Nielsen, Gunnrið Jóanesarson, Gisela Djurhuus